Baird analyst Jeff Johnson lowered the firm’s price target on Stryker to $319 from $330 and keeps an Outperform rating on the shares. The firm said the company remains on the cusp of numerous sizable new product launches that we believe should sustain strong top-line and margin performance well into 2024, keeping this a top idea across their medtech coverage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYK: